연구동향 분석

Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment

강성구 김승태 강석호 최인근 박영지 오상철 서재홍 천준 김준석 성득제 신상원 김열홍 박경화 이정현 2014년

논문상세정보
인용/피인용
' Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • cisplatinfailure
  • m-vacprotocol
  • second-line
  • urothelial carcinoma
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,265 0

0.0%

' Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment' 의 참고문헌

  • Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma : results of a large phase 2 study
    Vaughn DJ Cancer 115 : 4110 ~ 4117 [2009]
  • Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma : results of a large phase 2 study
    Vaughn DJ Cancer 115 4110-4117 [2009]
  • The updated EAU guidelines on muscle-invasive and metastatic bladder cancer
    Stenzl A Eur Urol 55 : 815 ~ 825 [2009]
  • The updated EAU guidelines on muscle-invasive and metastatic bladder cancer
    Stenzl A Eur Urol 55 815-825 [2009]
  • Systemic chemotherapy in inoperable or metastatic bladder cancer
    Bamias A Ann Oncol 17 : 553 ~ 561 [2006]
  • Systemic chemotherapy in inoperable or metastatic bladder cancer
    Bamias A Ann Oncol 17 553-561 [2006]
  • Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
    Sternberg CN Eur J Cancer 42 : 50 ~ 54 [2006]
  • Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
    Sternberg CN Eur J Cancer 42 50-54 [2006]
  • Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer
    Vaughn DJ J Clin Oncol 20 : 937 ~ 940 [2002]
  • Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer
    Vaughn DJ J Clin Oncol 20 937-940 [2002]
  • Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
    Kaufman D J Clin Oncol 18 : 1921 ~ 1927 [2000]
  • Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
    Kaufman D J Clin Oncol 18 1921-1927 [2000]
  • Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium : a trial of the Eastern Cooperative Oncology Group
    Dreicer R Cancer 97 : 2743 ~ 2747 [2003]
  • Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium : a trial of the Eastern Cooperative Oncology Group
    Dreicer R Cancer 97 2743-2747 [2003]
  • Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium
    Sweeney CJ J Clin Oncol 24 : 3451 ~ 3457 [2006]
  • Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium
    Sweeney CJ J Clin Oncol 24 3451-3457 [2006]
  • Phase 2 trial of epothilone B analog BMS-247550(ixabepilone)in advanced carcinoma of the urothelium(E3800) : a trial of the Eastern Cooperative Oncology Group
    Dreicer R Cancer 110 : 759 ~ 763 [2007]
  • Phase 2 trial of epothilone B analog BMS-247550(ixabepilone)in advanced carcinoma of the urothelium(E3800) : a trial of the Eastern Cooperative Oncology Group
    Dreicer R Cancer 110 759-763 [2007]
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer EA Eur J Cancer 45 : 228 ~ 247 [2009]
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer EA Eur J Cancer 45 228-247 [2009]
  • Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium : efficacy and patterns of response and relapse
    Sternberg CN Cancer 64 : 2448 ~ 2458 [1989]
  • Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium : efficacy and patterns of response and relapse
    Sternberg CN Cancer 64 2448-2458 [1989]
  • Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy
    Han KS Br J Cancer 98 : 86 ~ 90 [2008]
  • Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy
    Han KS Br J Cancer 98 86-90 [2008]
  • M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience
    Tannock I J Urol 142 (2 Pt 1) : 289 ~ 292 [1989]
  • M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience
    Tannock I J Urol 142 2 Pt 1 289-292 [1989]
  • Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    von der Maase H J Clin Oncol 23 : 4602 ~ 4608 [2005]
  • Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    von der Maase H J Clin Oncol 23 4602-4608 [2005]
  • Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
    Bajorin DF J Clin Oncol 17 : 3173 ~ 3181 [1999]
  • Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
    Bajorin DF J Clin Oncol 17 3173-3181 [1999]
  • Gemcitabine in transitional cell carcinoma of the urothelium
    von der Maase H Expert Rev Anticancer Ther 3 : 11 ~ 19 [2003]
  • Gemcitabine in transitional cell carcinoma of the urothelium
    von der Maase H Expert Rev Anticancer Ther 3 11-19 [2003]
  • Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer : results of a large, randomized, multinational, multicenter, phase III study
    von der Maase H J Clin Oncol 18 : 3068 ~ 3077 [2000]
  • Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer : results of a large, randomized, multinational, multicenter, phase III study
    von der Maase H J Clin Oncol 18 3068-3077 [2000]
  • European Organization for Research and Treatment. Overview of bladder cancer trials in the European Organization for Research and Treatment
    de Wit R Cancer 97 (8 Suppl) : 2120 ~ 2126 [2003]
  • European Organization for Research and Treatment. Overview of bladder cancer trials in the European Organization for Research and Treatment
    de Wit R Cancer 97 8 Suppl 2120-2126 [2003]
  • Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma
    Witte RS J Clin Oncol 15 : 589 ~ 593 [1997]
  • Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma
    Witte RS J Clin Oncol 15 589-593 [1997]
  • Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma
    Suyama T Jpn J Clin Oncol 39 : 244 ~ 250 [2009]
  • Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma
    Suyama T Jpn J Clin Oncol 39 244-250 [2009]
  • Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
    정규원 Cancer Research and Treatment 43 (1) : 1 ~ 11 [2011]
  • Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008
    정규원 Cancer Research and Treatment 43 1 1-11 [2011]
  • Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Bellmunt J Ann Oncol 22 (Suppl 6) : vi45 ~ vi49 [2011]
  • Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Bellmunt J Ann Oncol 22 Suppl 6 vi45-vi49 [2011]
  • Advanced bladder and urothelial cancers
    Raghavan D Eur J Cancer 36 (Suppl 2) : 1 ~ 6 [2000]
  • Advanced bladder and urothelial cancers
    Raghavan D Eur J Cancer 36 Suppl 2 1-6 [2000]